StillSteve
Active member
- Joined
- Apr 28, 2010
- Messages
- 41
- Reason
- PALS
- Diagnosis
- 02/2011
- Country
- US
- State
- MN
- City
- Twin Cities
I just started the Dexpramipexole phase III trial today in Minneapolis. I am patient number 10 at this location.
Two things of interest I learned from my doctor today:
- A second phase III trial (a second round?) for this drug will be started in areas not covered in the current round. She specifically mentioned Japan and India as countries where trial locations will be sited. She says that "often two phase III trials are done." She didn't use the word "round"--it's my interpretation that she's talking about "a second round of the phase III trial", but maybe I'm wrong and they really are considered to be two seperate trials. At any rate, she says the company is being very aggressive and has already picked (some?) sites for this new trial/round.
- She mentioned that they (the Minneapolis site) are applying to be included in a phase III trial of NP001. She didn't give any timeline. I told her that I was aware that Neuraltus had recently extended eligibility to those within 36 months of onset, and that I hoped I might be eligible to participate in this phase III trial of NP001. She was aware of the change, and didn't rule out the possibility of my participation in the NP001 phase III (she certainly didn't imply it would be likely, either).
Two things of interest I learned from my doctor today:
- A second phase III trial (a second round?) for this drug will be started in areas not covered in the current round. She specifically mentioned Japan and India as countries where trial locations will be sited. She says that "often two phase III trials are done." She didn't use the word "round"--it's my interpretation that she's talking about "a second round of the phase III trial", but maybe I'm wrong and they really are considered to be two seperate trials. At any rate, she says the company is being very aggressive and has already picked (some?) sites for this new trial/round.
- She mentioned that they (the Minneapolis site) are applying to be included in a phase III trial of NP001. She didn't give any timeline. I told her that I was aware that Neuraltus had recently extended eligibility to those within 36 months of onset, and that I hoped I might be eligible to participate in this phase III trial of NP001. She was aware of the change, and didn't rule out the possibility of my participation in the NP001 phase III (she certainly didn't imply it would be likely, either).